Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Amgen announced that the European Commission (EC) has granted conditional marketing authorization for BLINCYTO® (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL).
AstraZeneca announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease, an area of medicine outside AstraZeneca’s strategic focus.
The widespread misuse of skin creams and lotions that contain steroids in India is harmful and out of control, warns a Gujarat-based dermatologist.
Scientists have discovered a new compound that shows promise for treating deadly skin cancers like melanoma that are resistant or unresponsive to leading therapies today.
Japanese scientists have discovered a protein, found in humans, that has inhibitory effects on the human immuno-deficiency virus (HIV), the media reported on Wednesday.
The bacteria in your gut may help control when and how much you eat as researchers have found that 20 minutes after a meal they produce proteins that influence activation of appetite-regulating neurons in the brain.
The European Commission (EC) has approved Novartis' Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumour necrosis factor (anti-TNF) therapy.
Pfizer and IIT-Delhi on Tuesday said they have launched an incubation accelerator initiative at the later's campus for Indian startup companies as well as individuals.
[adsense:336x280:8701650588]
The U.S. Food and Drug Administration approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.
Amgen announced the European Commission (EC) granted marketing authorization for Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Kyprolis is the first irreversible proteasome inhibitor approved in the European Union (EU) for use in combination treatment of patients with relapsed multiple myeloma
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
